Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep;24(9):1713-1715.
doi: 10.1002/ejhf.2639. Epub 2022 Aug 12.

Echocardiographic tracking of transthyretin cardiomyopathy: which parameters matter the most?

Christian Nitsche  1
Affiliations
Free article
Editorial

Echocardiographic tracking of transthyretin cardiomyopathy: which parameters matter the most?

Christian Nitsche. Eur J Heart Fail. 2022 Sep.
Free article
No abstract available

PubMed Disclaimer

Comment on

  • Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis.
    Chacko L, Karia N, Venneri L, Bandera F, Passo BD, Buonamici L, Lazari J, Ioannou A, Porcari A, Patel R, Razvi Y, Brown J, Knight D, Martinez-Naharro A, Whelan C, Quarta CC, Manisty C, Moon J, Rowczenio D, Gilbertson JA, Lachmann H, Wechelakar A, Petrie A, Moody WE, Steeds RP, Potena L, Riefolo M, Leone O, Rapezzi C, Hawkins PN, Gillmore JD, Fontana M. Chacko L, et al. Eur J Heart Fail. 2022 Sep;24(9):1700-1712. doi: 10.1002/ejhf.2606. Epub 2022 Jul 27. Eur J Heart Fail. 2022. PMID: 35779241 Free PMC article.

References

    1. Chacko L, Karia N, Venneri L, Bandera F, Dal Passo B, Buonamici L, et al. Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. Eur J Heart Fail. 2022;24:1700-12.
    1. Rettl R, Mann C, Duca F, Dachs TM, Binder C, Ligios LC, et al. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022;23:767-80.
    1. Nitsche C, Aschauer S, Kammerlander AA, Schneider M, Poschner T, Duca F, et al. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. Eur J Heart Fail. 2020;22:1852-62.
    1. Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol. 2021;77:128-39.
    1. Nitsche C, Mascherbauer K, Calabretta R, Koschutnik M, Dona C, Dannenberg V, et al. Prevalence and outcomes of cardiac amyloidosis in all-comer referrals for bone scintigraphy. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.122.264041.